AKT1S1 and diabetic cardiomyopathy: A 2014 study by Mirko Volkers et al. on PRAS40, a direct mTORC1 inhibitor, reported diabetic cardiomyopathy prevention besides improved hepatic insulin sensitivity in a diabetic mouse model [74] but further PRAS40 studies in diabetic cardiac dysfunction are yet to emerge.